Nanoform, a nanoparticle medicine enabling company, has established Nanoform USA, a wholly owned subsidiary in the US. This is a natural progression for the company as it continues to increase the impact of its award-winning nanonisation technology and expand its pharma client base in the US.
The expansion coincides with increasing interest in Nanoform’s technology within the US marketplace and the company’s application for GMP status at its Finnish site, which is expected to further fuel demand for Nanoform’s proprietary CESS technology.
The establishment of Nanoform USA also follows the recent appointment of Sally Langa as Head of US Sales. Sally brings 30 years of valuable commercial experience in Pharma, having held senior positions at Catalent Pharma, Patheon and Halo Pharmaceutical.
Prof Edward Hæggström, Nanoform CEO, said: “We are tremendously excited to have officially established our presence in the US with a wholly owned subsidiary. This comes as a natural next step for our company as we continue to expand the reach of our nanonisation technology.”
Miguel Calado, Vice Chairman of the Nanoform Board, said: “I am thrilled we are establishing Nanoform USA Inc. With this strategic expansion, we now have a strong foundation on which to continue to grow our presence in the US.”
